The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
 
Antonio Cigliola
No Relationships to Disclose
 
Marco Moschini
No Relationships to Disclose
 
Valentina Tateo
No Relationships to Disclose
 
Chiara Mercinelli
No Relationships to Disclose
 
Damiano Patanè
No Relationships to Disclose
 
Emanuele Crupi
No Relationships to Disclose
 
Renzo Colombo
No Relationships to Disclose
 
Vincenzo Scattoni
No Relationships to Disclose
 
Giorgio Brembilla
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Francesco Montorsi
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Janssen; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme